Clinical trial / 2019
In aged men, oral nicotinamide riboside elevated the muscle NAD+ metabolome and lowered circulating inflammatory cytokines without altering bioenergetics.
In a randomized, double-blind, placebo-controlled crossover study, 12 aged men received 1 g per day of oral nicotinamide riboside (NR) or placebo for 21 days. Targeted metabolomics demonstrated that NR increased the muscle NAD+ metabolome, as shown by higher nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing showed downregulation of energy metabolism and mitochondrial pathways, though mitochondrial bioenergetics were not altered. Additionally, NR supplementation reduced circulating inflammatory cytokine levels.
- Study type
- Placebo-controlled, randomized, double-blind, crossover trial
- Who was studied
- 12 aged men
- What was measured
- Skeletal muscle NAD+ metabolome, muscle mitochondrial bioenergetics, muscle gene expression, and circulating inflammatory cytokines
THE PAPER
Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.
Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Cell Rep, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.